Elpiscience Files for Hong Kong IPO Focusing on Immunotherapy Pipeline
China-based Elpiscience Biopharmaceuticals, Inc. has filed for an initial public offering (IPO) with the Hong...
Elpiscience Biopharmaceuticals
Healthcare Firms Line Up for HKEX IPOs as Biotech Market Recovery Gains Momentum
A number of healthcare companies are seeking to capitalize on the recovering market conditions by...
Elpiscience Biopharmaceuticals Initiates Phase I Trial for Anti-LILRB2 Antibody ES009
Elpiscience Biopharmaceuticals, a China-based biopharmaceutical company, has announced that the first patient has been dosed...
Elpiscience Receives IND Approval for ES014 in China
Shanghai-based Elpiscience Biopharmaceuticals Inc. has announced receiving Investigational New Drug (IND) approval in China to...
WuXi Biologics Partners with Elpiscience for Macromolecule Development
China-based Contract Research, Development, and Manufacturing Organization (CRDMO) WuXi Biologics (HKG: 2269) has announced multiple...